Skip to main content

Table 1 List of acceptable chemotherapy regimens

From: Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study

Cancer type

Regimen and Dosing

Bladder cancer

M-VAC

Interval between cycles: 4 weeks

Cisplatin: 70 mg/m2

Doxorubicin: 30 mg/m2

Vinblastine: 3 mg/m2

Methotrexate: 90 mg/m2

Breast cancer

AC

Interval between cycles: 3 weeks

Cyclophosphamide: 600 mg/m2

Doxorubicin: 60 mg/m2

AC → P (sequential regimen) for the P (paclitaxel) cycles

Interval between cycles: 3 weeks

Paclitaxel: 175 mg/m2

AC → T (sequential regimen) for the T (docetaxel) cycles

Variant 1: AC → T

Interval between cycles: 4 weeks

Docetaxel: 100 mg/m2

Variant 2: AC → T

Interval between cycles: 1 week

Docetaxel: 35 mg/m2

AV

Interval between cycles: 3 weeks

Doxorubicin: 50 mg/m2

Vinolrebine: 50 mg/m2

CAPE-T

Interval between cycles: 3 weeks

Capecitabine: 35000 mg/m2

Docetaxel: 75 mg/m2

CMF

Interval between cycles: 4 weeks

Cyclophosphamide: 1400 mg/m2

Fluorouracil: 1200 mg/m2

Methotrexate: 80 mg/m2

EC

Interval between cycles: 3 weeks

Cyclophosphamide: 600 mg/m2

Epidoxorubicin: 100 mg/m2

FEC → T (sequential regimen) for the T (docetaxel) cycles only

Interval between cycles: 3 weeks

Docetaxel: 100 mg/m2

FEC

Interval between cycles: 4 weeks

Cyclophosphamide: 1050 mg/m2

Epirubicin: 120 mg/m2

Fluorouracil: 1000 mg/m2

P

Interval between cycles: 3 weeks

Paclitaxel: 250 mg/m2

EC → T (sequential regimen) for the T (docetaxel) cycles

Interval between cycles: 3 weeks

Docetaxel: 100 mg/m2

T

Interval between cycles: 3 weeks

Docetaxel: 100 mg/m2

TC

Interval between cycles: 3 weeks

Cyclophosphamide: 600 mg/m2

Docetaxel: 75 mg/m2

Cervical cancer

CDDP/PACLI

Interval between cycles: 3 weeks

Cisplatin: 50─75 mg/m2

Paclitaxel: 135 mg/m2

CDDP/TOPOTECAN

Interval between cycles: 3 weeks

Cisplatin: 50 mg/m2

Topotecan: 2.25 mg/m2

IRINOTECAN

Interval between cycles: 6 weeks

Irinotecan: 500 mg/m2

TOPOTECAN

Interval between cycles: 4 weeks

Topotecan: 7.5 mg/m2

Colorectal cancer

5FU/LEUCO

Interval between cycles: 4 weeks

Fluorouracil: 2125 mg/m2

Leucovorin: 100 mg/m2

FOLFIRI

Variant 1: FOLFIRI

Interval between cycles: 2 weeks

Fluorouracil: 2000─2400 mg/m2

Irinotecan: 180 mg/m2

Leucovorin: 200─400 mg/m2

Variant 2: FOLFIRI

Interval between cycles: 1 week

Fluorouracil: 2300 mg/m2

Irinotecan: 80 mg/m2

Variant 3: FOLFIRI

Interval between cycles: 2 weeks

Fluorouracil: 2000 mg/m2

Irinotecan: 180 mg/m2

FOLFOX

Interval between cycles: 2 weeks

Fluorouracil: 1600 mg/m2

Leucovorin: 200 mg/m2

Oxaliplatin: 85 mg/m2

Gastric cancer

CDDP/IRINO

Interval between cycles: 3 weeks

Cisplatin: 60 mg/m2

Irinotecan: 130 mg/m2

DOCE/IRINO

Interval between cycles: 3 weeks

Docetaxel: 30 mg/m2

Irinotecan: 140 mg/m2

ECF

Interval between cycles: 3 weeks

Epirubicin: 50 mg/m2

Cisplatin: 60 mg/m2

Fluorouracil: 200 mg/m2

ECX

Interval between cycles: 3 weeks

Epirubicin: 50 mg/m2

Cisplatin: 60 mg/m2

Capecitabin: 26250 mg/m2

EOF

Interval between cycles: 3 weeks

Epirubicin: 50 mg/m2

Oxaliplatin: 130 mg/m2

Fluorouracil: 200 mg/m2

EOX

Interval between cycles: 3 weeks

Epirubicin: 50 mg/m2

Oxaliplatin: 130 mg/m2

Capecitabine: 26250 mg/m2

FOLFOX

Interval between cycles: 2 weeks

Fluorouracil: 3400 mg/m2

Oxaliplatin: 100 mg/m2

Germ cell tumors

BEP followed by EP

Interval between cycles: 3 weeks

Bleomycin: 90 U

Cisplatin: 100 mg/m2

Etoposide: 500 mg/m2

CDDP/VP16

Interval between cycles: 3 weeks

Cisplatin: 100 mg/m2

Etoposide: 300─500 mg/m2

Hodgkin lymphoma

Stanford V

Interval between cycles: 4 weeks

Bleomycin: 10 U

Doxorubicin: 50 mg/m2

Etoposide: 120 mg/m2

Mechlorethamine: 6 mg/m2

Vinblastine: 12 mg/m2

Vincristine: 2.8 mg/m2

Non-Hodgkin lymphoma

ACOD

Interval between cycles: 3 weeks

Cyclophosphamide: 1000 mg/m2

Doxorubicin: 50 mg/m2

Vincristine: 2.4 mg/m2

CCOP

Interval between cycles: 4 weeks

Cyclophosphamide: 750 mg/m2

Liposomal Doxorubicin: 30 mg/m2

Vincristine: 2 mg/m2

CHOP

Interval between cycles: 2 or 3 weeks

Cyclophosphamide: 750–1200 mg/m2

Doxorubicin: 50–75 mg/m2

Vincristine: 1.4 mg/m2

DA-EPOCH

Interval between cycles: 3 weeks

Cyclophosphamide: 3750 mg/m2

Doxorubicin: 40 mg/m2

Etoposide: 200 mg/m2

Vincristine: 1.6 mg/m2

GMOX-R (with rituximab)

Interval between cycles: 2 or 3 weeks

Gemcitabine: 1000 mg/m2

Oxaliplatine: 100 mg/m2

GC

Variant 1:

Interval between cycles: 4 weeks

Cisplatin: 100 mg/m2

Gemcitabine: 3000 mg/m2

Variant 2:

Interval between cycles: 3 weeks

Cisplatin: 75 mg/m2

Gemcitabine: 2000 mg/m2

MEGACHOP (with rituximab)

Interval between cycles: 3 weeks

Cyclophosphamide: 1200 mg/m2

Doxorubicin: 75 mg/m2

Vincristine: 2 mg/m2

RFM (with rituximab)

Interval between cycles: 4 weeks

Fludarabine: 75 mg/m2

Mitoxantrone: 10 mg/m2

Non-small cell lung cancer

Carbo/PACLI

Interval between cycles: 3 weeks

Carboplatin: 6 AUC

Paclitaxel: 200 mg/m2

CDDP/DOCE

Interval between cycles: 3 weeks

Cisplatin: 75 mg/m2

Docetaxel: 75 mg/m2

CDDP/PACLI

Interval between cycles: 3 weeks

Cisplatin: 50─75 mg/m2

Paclitaxel: 135 mg/m2

CDDP/VNR

Variant 1: CDDP/VNR

Interval between cycles: 4 weeks

Cisplatin: 100 mg/m2

Vinorelbine: 100 mg/m2

Variant 2: CDDP/VNR

Interval between cycles: 4 weeks

Cisplatin: 100 mg/m2

Vinorelbine: 120 mg/m2

CDDP/VP16

Interval between cycles: 3 weeks

Cisplatin: 100 mg/m2

Etoposide: 300─500 mg/m2

VIG

Variant 1: VIG

Interval between cycles: 3 weeks

Gemcitabine: 1800 mg/m2

Ifosfamide: 3000 mg/m2

Navelbine: 45 mg/m2

Variant 2: VIG

Interval between cycles: 3 weeks

Gemcitabine: 2000 mg/m2

Ifosfamide: 3000 mg/m2

Navelbine: 50 mg/m2

T

Interval between cycles: 3 weeks

Docetaxel: 75 mg/m2

Occult primary adenocarcinoma

DOCE/GEMCI

Interval between cycles: 3 weeks

Docetaxel: 75 mg/m2

Gemcitabine: 2000 mg/m2

Esophageal cancer

CDDP/IRINO

Interval between cycles: 3 weeks

Cisplatin: 60 mg/m2

Irinotecan: 130 mg/m2

ECF

Interval between cycles: 3 weeks

Epirubicin: 50 mg/m2

Cisplatin: 60 mg/m2

Fluorouracil: 200 mg/m2

ECX

Interval between cycles: 3 weeks

Epirubicin: 50 mg/m2

Cisplatin: 60 mg/m2

Capecitabin: 26250 mg/m2

EOF

Interval between cycles: 3 weeks

Epirubicin: 50 mg/m2

Oxaliplatin: 130 mg/m2

Fluorouracil: 200 mg/m2

EOX

Interval between cycles: 3 weeks

Epirubicin: 50 mg/m2

Oxaliplatin: 130 mg/m2

Capecitabine: 26250 mg/m2

Ovarian cancer

CARBO/DOCE

Interval between cycles: 3 weeks

Carboplatin: 5 AUC

Docetaxel: 75 mg/m2

CARBO/PLACLI → TOPOTECAN (sequential treatment) only for the topotecan cycles

Interval between cycles: 3 weeks

Topotecan: 7.5 mg/m2

TOPOTECAN

Interval between cycles: 3 weeks

Topotecan: 7.5 mg/m2

Pancreatic cancer

GEMCI/IRINO

Interval between cycles: 3 weeks

Gemcitabine: 2000 mg/m2

Irinotecan: 300 mg/m2

Prostate cancer

CABAZITAXEL

Interval between cycles: 3 weeks

Cabazitaxel: 25 mg/m2

T

Interval between cycles: 3 weeks

Docetaxel: 75─100 mg/m2

Small-cell lung cancer

CARBO/VP16

Interval between cycles: 3 weeks

Carboplatin: 300 mg/m2

Etoposide: 900 mg/m2

CAV

Interval between cycles: 3 weeks

Cyclophosphamide: 750 mg/m2

Doxorubicin: 40 mg/m2

Vincristine: 1.3 mg/m2

CDE

Interval between cycles: 3 weeks

Cyclophosphamide: 1000 mg/m2

Doxorubicin: 45 mg/m2

Etoposide: 300 mg/m2

CDDP/VP16

Interval between cycles: 3 weeks

Cisplatin: 100 mg/m2

Etoposide: 300─500 mg/m2

Soft tissue sarcoma

T

Interval between cycles: 3 weeks

Docetaxel: 100 mg/m2

Uterine cancer

T

Interval between cycles: 3 weeks

Docetaxel: 100 mg/m2